On Friday, Shares of Chesapeake Energy Corporation (NYSE:CHK), gained 5.27% to $7.39.
Chesapeake Energy Corporation has been given an average recommendation of “Hold” by the thirty-two ratings firms that are presently covering the company, Market Beat.com reports. Seven analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation, and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.73.
Chesapeake Energy Corporation produces oil and natural gas through acquisition, exploration, and development of from underground reservoirs in the United States.
Shares of Boston Scientific Corporation (NYSE:BSX), inclined 0.77% to $17.07, during its last trading session.
Boston Scientific Corporation has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable cardioverter defibrillator (ICD) and the X4 cardiac resynchronization therapy defibrillator (CRT-D) systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.
Patients with implantable cardiac devices have a wide variety of diagnostic imaging available to them, counting x-rays and CT scans, but Boston Scientific systems had not been evaluated as MRI conditional. This new system labeling, referred to as ImageReady™ MR Conditional devices, stipulates the conditions under which the systems are considered safe for use in a MRI setting.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Finally, Monsanto Company (NYSE:MON), ended its last trade with -0.02% loss, and closed at $98.38.
While Monsanto Company continues to believe a combination with Syngenta (SYNN.VX) would have created tremendous value for shareowners of both companies and farmers, Syngenta has communicated that Monsanto’s improved proposal did not meet Syngenta’s financial expectations. Without a basis for constructive engagement from Syngenta, Monsanto will continue to focus on its growth opportunities built on its existing core business to deliver the next wave of transformational solutions for agriculture.
Monsanto confirmed it communicated a revised proposal on August 18 to Syngenta to combine the two companies. The improved proposal, subject to due diligence and other customary conditions, comprised a number of elements counting the following:
- Monsanto’s new proposal raised the cash component of the projected transaction to CHF 245 per share. The proposal also maintained the same number of shares as in its April proposal, providing Syngenta shareowners with an approximate 30 percent ownership in the new company. Based on Monsanto’s share price and currency exchange rates at the time, the revised proposal translated to a value of CHF 470 per share.
- Given the confidence the transaction would close and to provide additional protection from closing risk, the proposal raised the reverse break-up fee to $3 billion. The reverse break-up fee would have been payable by Monsanto if it would have been unable to obtain necessary global regulatory approvals.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
